Work

Safety and immunogenicity of Anti PD-L1 (Atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: an NRG Oncology trial (024)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/s0090-8258(22)01242-2

Authors: Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather Lankes, Giulio Pesci, Kay Park, Barbara Banbury, Ned Sherry, Sharad Ghamande, Laura Holman, Cara Mathews, Roisin O’Cearbhaill, Carol Aghajanian, Russell Schilder

Institutions: University of California San Diego, Memorial Sloan Kettering Cancer Center, NRG Oncology, Adaptive Biotechnologies (United States), Augusta University, University of Oklahoma, Brown University, Thomas Jefferson University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4297776380

FWCI: 1.367

Cites:

Cited by: 16

Related to: 10